Clinical Trial

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-02-02; most recent amendment 2026-02-02.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-10-21
Trial Details
NCT Number NCT04740476
Lead Sponsor Stoke Therapeutics, Inc
Conditions Dravet Syndrome
Enrollment 60 participants
Start Date 2021-01-20
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-04